Indirect effects of cytomegalovirus infection: Implications for vaccine development

Philip Moseley; Paul Klenerman; Seilesh Kadambari

doi:10.1002/rmv.2405

Indirect effects of cytomegalovirus infection: Implications for vaccine development

Rev Med Virol. 2023 Jan;33(1):e2405. doi: 10.1002/rmv.2405. Epub 2022 Nov 15.

Authors

Philip Moseley¹, Paul Klenerman^{2

3}, Seilesh Kadambari^{4

5

6

7}

Affiliations

¹ Department of Paediatrics, Horton General Hospital, Oxford University Hospitals, Banbury, UK.
² Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
³ Nuffield Department of Medicine, University of Oxford, Oxford, UK.
⁴ Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK.
⁵ NIHR Oxford Biomedical Research Centre, Oxford, UK.
⁶ Department of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
⁷ Great Ormond Street Institute of Child Health, University College London, London, UK.

Abstract

Development of a cytomegalovirus (CMV) vaccine is a high priority due to its significant global impact-contributing to mortality in immunosuppressed individuals, neurodevelopmental delay in infected neonates and non-genetic sensorineural hearing loss. The impact of CMV on the general population has been less well studied; however, a wide range of evidence indicates that CMV may increase the risk of atherosclerosis, cancer, immunosenescence, and progression of tuberculosis (TB) and human immunodeficiency virus. Due to the high seroprevalence of CMV worldwide, any modulation of risk by CMV is likely to have a significant impact on the epidemiology of these diseases. This review will evaluate how CMV may cause morbidity and mortality outside of the neonatal and immunosuppressed populations and consider the potential impact of a CMV vaccine on these outcomes.

Publication types

Review

MeSH terms

Cytomegalovirus Infections* / epidemiology
Cytomegalovirus Infections* / prevention & control
Cytomegalovirus Vaccines*
Humans
Infant, Newborn
Seroepidemiologic Studies
Vaccine Development

Substances

Cytomegalovirus Vaccines